Hypo-RESOLVE — Funders


The Innovative Medicines Initiative (IMI) is Europe’s largest public-private initiative aiming to improve health by speeding up the development of, and patient access to, innovative medicines, particularly in areas where there is an unmet medical or social need. IMI facilitates collaboration between the key players involved in healthcare research, including universities, the pharmaceutical and other industries, small and medium-sized enterprises (SMEs), patient organisations, and medicines regulators. It is a partnership between the European Union (represented by the European Commission) and the European pharmaceutical industry (represented by EFPIA, the European Federation of Pharmaceutical Industries and Associations). Through the IMI 2 programme, IMI has a budget of € 3.3 billion for the period 2014-2024. Half of this comes from the EU’s research and innovation programme, Horizon 2020. The other half comes from large companies, mostly from the pharmaceutical sector; these do not receive any EU funding, but contribute to the projects ‘in kind’, for example by donating their researchers’ time or providing access to research facilities or resources.

Within Hypo-RESOLVE, the European Union and the European Federation of Pharmaceutical Industries and Associations (EFPIA), T1D Exchange, JDRF, International Diabetes Federation (IDF), The Leona M. and Harry B. Helmsley Charitable Trust invest approx. €26.8mio over the next four years.

T1D Exchange

Unitio, Inc. (Unitio) is a nonprofit organization that unites those affected by disease with those committed to advancing better care and treatments in order to improve outcomes. The Organization’s flagship program, T1DExchange, functions as a research organization dedicated to accelerating therapies and improving care for people affected by type 1 diabetes.

T1D Exchange actively supports discovery and innovation—particularly at its earliest stages. At the same time, the organization asserts that evidence gathered in the “real world” is necessary to help bridge the gap between discovery in research settings and impact in people’s lives.

The T1D Exchange model uses cutting-edge research tools, methods, and programs to gather biological samples from people living with type 1 diabetes, as well as evidence from their real-world and clinical experiences. The goal is to link patient samples, data, and insight to all stage of research and development, advancing the development of therapies and better care for everyone affected by type 1 diabetes.


JDRF is the leading global organization funding type 1 diabetes (T1D) research. The ongoing dedication to JDRF's mission to accelerate life-changing breakthroughs to cure, prevent and treat T1D and its complications ensures that there will be a continuous stream of life-changing therapies moving from development through to the marketplace that lessen the impact of T1D. We want to keep people with T1D healthy and safe today until we reach our ultimate goal of a cure and universal prevention of T1D and turn Type One into Type None.

JDRF collaborates with a wide spectrum of partners at every stage of the drug and device delivery pipeline and is the only organization with the scientific resources, regulatory influence, and a strategic plan to deliver a world without T1D. JDRF’s influence and leadership extends beyond funding research. We strategically partner with industry, governments, foundations, academia, and clinicians, because curing T1D is a global coordinated effort with JDRF leading the effort.

Currently, JDRF is supporting $568 million in active T1D research projects worldwide. In 2016 alone, JDRF’s T1D research funding totaled more than $106 million. JDRF now has more than 570 research projects taking place throughout the globe. JDRF’s 2016 research funding included $78 million in U.S.-based projects and $28 million in international projects. Since its founding in 1970, JDRF’s cumulative research funding totals over $2 billion. JDRF is currently funding more than 50 clinical trials of potential T1D therapies.

The International Diabetes Federation

The International Diabetes Federation (IDF) is an umbrella organisation of over 240 national diabetes associations in some 170 countries and territories. It represents the interests of the growing number of people with diabetes and those at risk. The Federation has been leading the global diabetes community since 1950. IDF’s mission is to promote diabetes care, prevention and a cure worldwide. IDF is engaged in action to tackle diabetes from the local to the global level ― from programmes at community level to worldwide awareness and advocacy initiatives. The Federation’s activities aim to influence policy, increase public awareness and encourage health improvement, promote the exchange of high-quality information about diabetes, and provide education for people with diabetes and their healthcare providers. IDF is associated with the Department of Public Information of the United Nations and is in official relations with the World Health Organization (WHO).

The Leona M. and Harry B. Helmsley Charitable Trust

The Helmsley Charitable Trust aspires to improve lives by supporting exceptional efforts in the U.S. and around the world in health and select place-based initiatives. Since beginning active grantmaking in 2008, Helmsley has committed more than $2 billion for a wide range of charitable purposes. Helmsley’s Type 1 Diabetes Program was established with the goal of improving the lives of all people living with type 1 diabetes (T1D). It is one of the largest private foundation funders of T1D in the nation. Working closely with key players across the T1D ecosystem – patients, physicians, researchers, caregivers, researchers, government agencies, funders, pharmaceutical companies, device makers, and community organizations – we seek to improve care and ultimately prevent the disease. We hope to do so by supporting innovative projects that are high-risk, high-reward, and have a long-term vision. We encourage bold thinking and new approaches, supporting projects that others cannot fund but have a clear impact on the lives of people with T1D.